HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

CEO James Kilts has extended his employment contract one year to Jan. 19, 2005 from original three-year contract's expiration on Jan. 19, 2004, Gillette reports Aug. 7. Principle terms of the contract extension call for Kilts to receive a stock option award of 1 mil. shares on Jan. 2 and stock appreciation rights of 1 mil. share units that have a roughly six-month valuation term, firm notes. Exec's current base compensation is about $1.4 mil. with a bonus targeted at $1.7 mil. in 2003. Kilts was appointed to the helm in early 2001 (1"The Rose Sheet" Jan. 29, 2001, p. 7). Separately, Gillette announced it acquired a majority interest in Fujian Nanping Nanfu Battery, a leading Chinese battery company. The acquisition will be nominally accretive to 2003 earnings, firm notes...

You may also be interested in...

Gillette Mach3 Sales Boost In Q4 Provides Momentum For CEO Kilts

Gillette's Mach3 men's razor and blade record 38% sales increase in the fourth quarter provides momentum for newly appointed CEO James Kilts to build an era of "sustained, profitable growth" after he assumes the helm of the firm Feb. 12.

Ex-Cipla Executive To Helm JB Chemicals

The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.

Coronavirus Update: Moderna And Pfizer Respond To Vaccine Trial Transparency Demands

Moderna led by releasing the trial protocol for its COVID-19 vaccine study, followed by Pfizer, as industry faces demands for transparency.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts